Description
Myostan (YK-11) 5 mg Driada Medical — Precision-dosed for consistent results, a unique compound that functions as both a partial SARM and a myostatin inhibitor. By inhibiting the myostatin protein — the body’s natural limiter of muscle growth — YK-11 theoretically unlocks genetic muscle-building potential beyond what conventional SARMs or steroids can achieve. It also increases follistatin expression, further antagonizing myostatin’s muscle-limiting effects. This formulation is dosed at 5 mg per unit.
Key Benefits
- Myostatin inhibitor — uncommon mechanism vs other SARMs
- Strong lean-mass gains in 8 weeks
- Hepatotoxic — more so than other SARMs
- HPTA suppression meaningful at 10+ mg/day
- Not a beginner SARM — bloodwork at week 4
- Each unit dosed at 5 mg — see Recommended Dosage below for protocol-specific intake
Recommended Dosage
Research dosing: 5–15 mg/day for 8 weeks. Single daily dose. Split 2× for smoother serum if ALT/AST rise. Full PCT required.
How It Works
Steroidal SARM with added myostatin inhibition — mechanism more similar to follistatin agonists than standard SARMs. Potent mass-builder with distinctive “fullness” effect.
Pharmacokinetics
Plasma half-life approximately 12 hours. Twice-daily dosing smooths serum levels.
Potential Side Effects
Hepatotoxic — more than other SARMs. ALT/AST at week 4 mandatory. HPTA suppression. TUDCA support advised. HDL hit.
Cycle & Stacking Guide
8-week cycles, 5–10 mg/day for most users. Full PCT (Nolva 20 mg/day × 4 weeks). Stacks with Ostarine or Ligandrol for enhanced recomp.
Manufacturer Notes
Driada Medical positions itself at the affordable end of the market while maintaining third-party lab verification. Their vial caps carry a tamper-seal date code; batch COAs available through the distributor.
Storage & Handling
Store at recommended temperature (15–25°C; peptides and HGH at 2–8°C after reconstitution). Protect from light and moisture. Keep out of reach of children. For research and educational purposes only.
Reviews
There are no reviews yet.